Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
NEW YORK, Feb. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Cardiovascular Systems, Inc. (NASDAQ:CSII) securities between September 12, 2011 and January 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cardiovascular-systems. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cardiovascular-systems.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
